<DOC>
	<DOCNO>NCT01949363</DOCNO>
	<brief_summary>This study Phase I , open label , non-randomized , dose-frequency escalation pharmacokinetics study among 24 healthy male female subject , age 18 45 year determine pharmacokinetics safety high- , multi-dose cefixime treatment reduce susceptibility gonorrhea . Stage 1 ( Cohorts A B ) examine pharmacokinetics single 400mg 800mg dose cefixime . Stage 2 ( Cohorts C D ) subject take 800mg cefixime every 12 hour 2 dos . If dose regimen well tolerate , dose-frequency escalate 800mg every 8 hour 3 dos , serum level cefixime measure . Study duration approximately 47 week .</brief_summary>
	<brief_title>The Pharmacokinetics Extended Duration High-dose Cefixime Decreased Susceptibility Neisseria Gonorrhoeae : A Phase I Pilot Study</brief_title>
	<detailed_description>This study Phase I , open label , non-randomized , dose-frequency escalation pharmacokinetics study among 24 healthy male female subject , age 18 45 year determine pharmacokinetics safety high multi-dose cefixime treatment reduce susceptibility gonorrhea . The study occur two stage describe . Stage 1 : Confirm/establish pharmacokinetics ( PK ) 400mg 800mg dos cefixime tablet . Stage 2 : Define dose frequency necessary achieve total serum cefixime level exceed 2.0 mcg/mL 20 hour . Stage 1 ( Cohorts A B ) : Six subject admit Johns Hopkins Bayview Clinic Trials Unit assess dose regimen , total 12 subject . At time=0 , subject undergo baseline serum cefixime level , follow ingestion cefixime . Serum collection occur time 0 , 1 , 2 , 4 , 8 , 12 , 16 , 20 , 24 hour . Cohort B serum collection time point Cohort A . Cohorts A &amp; B run nearly simultaneously logistically feasible . Stage 2 ( Cohorts C D ) : After determine PK parameter single dose 800mg , PK simulation model repeat , adjust model need base finding study Stage 1 . Assuming major discrepancy Figure 2 ( ) new PK simulation , follow regimen test , begin Cohort C. Six subject per dose regimen , Cohorts C D , admit Johns Hopkins Bayview Medical Center , total 12 subject . The 800mg q12 hour x 2 regimen ( Cohort C ) test first . For Cohort C , serum cefixime level draw 12 , 16 , 26 hour . If q12 regimen deem safe tolerable review SMC , Cohort D commence 800mg q8 hour x 3 regimen . Total serum cefixime level draw Cohort D 8 , 16 , 20 26 hour ( see Section 7.2 ) . All Stages , All Cohorts : All sample collect PK analysis ship University Toledo , Dr. Jeffrey Blumer 's HPLC lab processing . Specimens analyzed high performance liquid chromatography ( HPLC ) total cefixime concentration level . Targeted clinical evaluation use monitor subject report side effect . Subjects ask specific symptom may experience , include abdominal pain , nausea , vomit , diarrhea , flatulence , headache , rash , symptom . Additionally , subject ask maintain Subject Diary ( Appendix E ) Study Day 0 Day 7 record information symptom experience medication take . Study duration approximately 47 week .</detailed_description>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Cefixime</mesh_term>
	<criteria>Healthy male female subject 18 45 year , inclusive Ability understand consent process procedure Informed consent obtain sign Body mass index ( BMI ) &lt; 35 kg/m^2 Subjects agree available study visit Negative Breathalyzer Agreement female subject reproductive potential use adequate method contraception study 30 day study drug administration . Female subject must agree use TWO reliable method contraception receive study drug 30 day study drug administration sexually active , include : condom , spermicidal gel , diaphragm , hormonal nonhormonal intrauterine device , surgical sterilization , oral contraceptive pill ( OCP ) , depot progesterone injection . Subjects take prescription medication regular basis ( except oral contraceptive , OCPs ) , include limited , antipsychotic , antidepressant , antiepileptic , cardiac medication , antihypertensive etc . Medical condition precludes participation , include follow : Hypertension confirm systolic blood pressure &gt; 140 mmHg confirm diastolic blood pressure &gt; 90 mmHg , measure 10 15 minute rest Morbid obesity ( BMI &gt; /=35 ) Current diagnosis pulmonary disease History current diagnosis diabetes Autoimmune disorder , lupus , Wegener 's , rheumatoid arthritis History malignancy except lowgrade skin cancer , ( i.e. , basal cell carcinoma think cure ) Known diagnosis prolong QT interval History alcohol abuse History seizure disorder History renal disease Chronic renal , hepatic , pulmonary disease condition could interfere absorption study drug predispose adverse gastrointestinal event ( e.g. , surgical resection significant proportion stomach bowel , gastric bypass , gastric banding , irritable bowel syndrome , inflammatory bowel disease ) Positive serology result HIV , HBsAg , HCV antibodies Subjects take prescription drug previous 14 day within 5 halflives dose Ingestion counter medication herbal supplement within 7 day dose Positive urine toxicology marijuana , cocaine , amphetamine , opiate , PCP , barbiturates benzodiazepine History allergic reaction intolerance cephalosporins History allergic reaction penicillin ( stage ) Subjects allergy macrolides may participate Stage 3 Subjects QTc &gt; 450ms ( Fridericia 's correction ) screen ECG may participate Stage 3 . Positive pregnancy test ; pregnant nursing woman Screening laboratory test outside acceptable limit present Appendix C Any specific condition , judgment Investigator , preclude participation could affect subject safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Gonococcal Infections , Cefixime , Neisseria gonorrhoeae , Azithromycin , antibiotic , cephalosporin</keyword>
</DOC>